Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Novartis sales and marketing update

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cancer Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in two dossier assessments that no added benefit is proven for Mekinist …

    Published on 1/25/2016
  • Takara Bio sales and marketing update

    Takara Bio Inc. (Tokyo:4974), Shiga, Japan Business: Functional genomics Takaras Clontech Laboratories Inc. subsidiary launched the Guide-it CRISPR/Cas9 Gesicle production system for the delivery of Cas9 and gene-…

    Published on 1/25/2016
  • Allergan, Ironwood sales and marketing update

    Allergan plc (NYSE:AGN), Dublin, Ireland Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. Business: Gastrointestinal Allergan launched Viberzi eluxadoline in the U.S. to treat irritable bowel syndrome with …

    Published on 1/18/2016
  • Biogen, Swedish Orphan Biovitrum sales and marketing update

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden Business: Hematology Swedish Orphan launched Elocta in Denmark and Germany as on-demand and prophylactic treatment of…

    Published on 1/18/2016
  • Exact Sciences, Anthem sales and marketing update

    Exact Sciences Corp. (NASDAQ:EXAS), Madison, Wis. Anthem Inc. (NYSE:ANTM), Indianapolis, Ind. Business: Diagnostic Anthem Blue Cross of California will cover Cologuard colon cancer screening test from Exact Sciences as …

    Published on 1/18/2016
  • Octapharma sales and marketing update

    Octapharma AG, Lachen, Switzerland Business: Hematology Octapharma launched Nuwiq human recombinant coagulation Factor VIII in the U.S. for on-demand treatment and control of bleeding episodes; perioperative management …

    Published on 1/18/2016
  • OvaScience sales and marketing update

    OvaScience Inc. (NASDAQ:OVAS), Cambridge, Mass. Business: Endocrine/Metabolic OvaScience said its Augment fertility treatment is being offered in Japan through a preceptorship program at the IVF Japan fertility clinic …

    Published on 1/18/2016
  • Relypsa sales and marketing update

    Relypsa Inc. (NASDAQ:RLYP), Redwood City, Calif. Business: Endocrine/Metabolic Relypsa launched Veltassa patiromer in the U.S. to treat hyperkalemia. The wholesale acquisition cost (WAC) for the high-capacity oral …

    Published on 1/11/2016
  • Amgen sales and marketing update

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Endocrine/Metabolic Germany's Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier assessment that Repatha evolocumab from Amgen …

    Published on 1/4/2016
  • Clinigen Group, Sunesis sales and marketing update

    Clinigen Group plc (LSE:CLIN), Burton-on-Trent, U.K. Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS), South San Francisco, Calif. Business: Cancer Clinigen's Idis Managed Access division partnered with Sunesis to manage a …

    Published on 1/4/2016
  • Foundation Medicine, UnitedHealth Group sales and marketing update

    Foundation Medicine Inc. (NASDAQ:FMI), Cambridge, Mass. UnitedHealth Group Inc. (NYSE:UNH), Minneapolis, Minn. Business: Pharmacogenetics UnitedHealthcare will cover Foundation's FoundationOne genomic profiling assay …

    Published on 1/4/2016
  • Genentech, Roche sales and marketing update

    Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Cancer The U.K.'s NICE issued final guidance recommending against Kadcyla trastuzumab emtansine from Roches …

    Published on 1/4/2016
  • GlaxoSmithKline, Novo Nordisk sales and marketing update

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Business: Inflammation The Institute for Clinical and Economic Review (ICER), a U.S.-based non-profit that …

    Published on 1/4/2016
  • Santen sales and marketing update

    Santen Pharmaceutical Co. Ltd. (Tokyo:4536), Osaka, Japan Business: Ophthalmic The U.K.'s NICE issued final guidance recommending Ikervis ciclosporin from Santen to treat severe keratitis in adults with dry eye disease …

    Published on 1/4/2016
  • BioMarin sales and marketing update

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), San Rafael, Calif. Business: Endocrine/Metabolic The Highly Specialised Technologies (HST) Evaluation Committee of the U.K.s NICE issued a final draft guidance provisionally …

    Published on 12/21/2015
  • Eli Lilly sales and marketing update

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Cancer Eli Lilly launched lung cancer drug Portrazza necitumumab in the U.S. at a wholesale acquisition cost (WAC) of $8,000 per three-week treatment cycle. …

    Published on 12/21/2015
  • J&J, PharmaMar sales and marketing update

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. PharmaMar S.A. (Madrid:PHM), Madrid, Spain Business: Cancer The U.K.s NICE issued preliminary draft guidance recommending Johnson & Johnsons Caelyx pegylated liposomal …

    Published on 12/21/2015
  • Regeneron, Sanofi, UnitedHealth Group sales and marketing update

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France UnitedHealth Group Inc. (NYSE:UNH), Minneapolis, Minn. Business: Endocrine/Metabolic Regeneron and Sanofi said…

    Published on 12/21/2015
  • Valeant Pharmaceuticals, Walgreens Boots Alliance Inc. sales and marketing update

    Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Laval, Quebec Walgreens Boots Alliance Inc. (NASDAQ:WBA), Deerfield, Ill. Business: Supply/Service Valeant announced a 20-year distribution agreement with …

    Published on 12/21/2015
  • BTG, J&J sales and marketing update

    BTG plc (LSE:BTG), London, U.K. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer The U.K.s NICE issued a second final appraisal determination (FAD) recommending against the use of Zytiga abiraterone …

    Published on 12/14/2015
  • Medivation, Astellas sales and marketing update

    Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Cancer The U.K.s NICE issued final draft guidance recommending Xtandi enzalutamide from Astellas to treat …

    Published on 12/14/2015
  • NeoGenomics sales and marketing update

    NeoGenomics Inc. (NASDAQ:NEO), Fort Myers, Fla. Business: Genomics NeoGenomics launched its NeoLAB Solid Tumor Monitor test to quantify and track genomic abnormalities in tumors and its NeoLAB BTK Inhibitor Acquired …

    Published on 12/14/2015
  • Alexion sales and marketing update

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Business: Endocrine/Metabolic The U.K.s NICE issued draft guidance recommending against Strensiq asfotase alfa from Alexion to treat pediatric-onset …

    Published on 12/7/2015
  • Amgen, CVS Health Corp sales and marketing update

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. CVS Health Corp (NYSE:CVS), Woonsocket, R.I. Business: Endocrine/Metabolic CVS has selected Repatha evolocumab from Amgen as its exclusive PCSK9 inhibitor in exchange for…

    Published on 12/7/2015
  • Helsinn, Eisai sales and marketing update

    Helsinn Healthcare S.A., Lugano, Switzerland Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Gastrointestinal Helsinn and Eisai said the American Society of Clinical Oncology (ASCO) has recognized Akynzeo …

    Published on 12/7/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993